Insights
At Inbeeo, Market Access truly is our passion and we love to share our thoughts on the latest developments in the field through our blog and also in publications. Should you have a topic that you would value our thoughts on then please do get in touch – we would love to hear from you.


European Hospital Exemption Pathways for ATMPs : Implementation and Impact
Hospital Exemptions for ATMPs can fill an unmet need for patients. However, varied implementation and unclear guidance can negatively impact sustainable patient access.

Using the Hospital Exemption Pathway to improve patient access to ATMPs in Europe
More alignment is needed to ensure that the Hospital Exemption Pathway is used to fill gaps where commercial ATMPs are lacking, for more sustainable and equal access to safe ATMPs.

Fast-track reimbursement in Europe: Six reasons why manufacturers don’t use it
Manufacturers don’t use fast-track reimbursement in Europe. Although this seems like an oversight, there are six reasons explaining why it is not happening.

Five reasons why you need a strategic market access consultant
A strategic market access consultant won’t create a strategy for you but can help a great deal in optimal decision making and saving money down the road. Here are 5 reasons why you need one.

Global value dossiers are missing the access part of the story
With its focus on value, a traditional Global Value Dossier reinforces a common pitfall in clinical development and commercialisation. This is the idea that if

A tailored approach to estimate the outlook of the gene therapy market
Using epidemiological data, a patient-based forecasting model projected the gene therapy market outlook until 2036, evaluating global developments and their impact. Despite uncertainties, it emphasized the importance of preparedness and sustainability for public health resource stakeholders.

Advanced Access for Advanced Therapies
Out with the old, in with the new. What worked for small molecules and MAbs is irrelevant. We co-hosted this webinar with Impatient to help the audience uncover strategic frameworks, tailored for ATMP access challenges.

Will Europe Miss The Boat On ATMPs?
Europe is lagging behind in the adoption of ATMPs, as seen in its low profitability and R&D spending compared to other regions. This is largely due to the challenges faced in clinical assessments of ATMPs and the need for innovative pricing and reimbursement pathways to ensure early patient access.

Team Inbeeo Ready For ISPOR Europe 2022 in Vienna
Team Inbeeo is ready for ISPOR Europe 2022 in Vienna.

More than just price cuts: Improving access to essential cancer drugs in low and lower-middle-income countries
Simply making essential cancer medicines more affordable does not guarantee that patients will receive the right medicine at the right time. Whilst essential cancer medicines are almost universally available in developed markets, what is industry currently doing to facilitate access to these medicines in LLMICs, who perhaps need it most?

How should pharmaceutical companies prepare for the upcoming joint EU HTA?
The Health Technology Assessment landscape is changing in the EU – soon a single standardised assessment will be used across all member states. January 2022

Day in the life of a consultant at Inbeeo
Join Sarah, Associate Consultant at Inbeeo, as she works to solve exciting market access challenges for our global life sciences clients.

Inbeeo has been honoured with a Queen’s Award for Enterprise: International Trade
Inbeeo’s commitment to delivering stellar strategic thinking for global life sciences companies has been recognized by the top business award

France to Adopt a Market Access Pathway Like the German System
France’s Health Innovation 2030 Plan Proposes to Adopt a Market Access Pathway Like the German System to Accelerate Patient Access to Innovative Medicines – What Changes Can Be Expected?

Rare Disease Day 2021: UK Roadmap to Improving Care for Rare Disease Patients
Earlier this year, the UK government announced the Rare Diseases Framework, outlining strategy to improve the delivery of care to the 3.5 million people living within the four nations of the UK with a rare disorder.

Unpacking the biotech sector: What sets this sector apart and what are the challenges
All eyes were on pharma biotech companies in 2020, as they raced against each other to find solutions to alleviate the Covid-19 pandemic through vaccines and treatments.

How are payers adapting to the ATMP revolution?
Our CEO Herve Lillu recently led a discussion on this topic at the 2020 World Pharma pricing, Evidence, and Market Access Congress. Before we get

Four Market Access Measures Triggered by COVID-19 That Are Here To Stay
Many market access decisions were intended to provide rapid one-off answers to one of the most extraordinary situations healthcare systems have ever had to face, but some of them are telling us something about the more profound changes that are likely to affect pharmaceutical market access in the longer run.

Reflections on The Initial Impact of COVID-19 on Global Market Access Activities
Inbeeo dives into the data from our COVID-19 Impact on Market Access Activities Dashboard and identifies three positive trends that emerged.

WEBINAR REPLAY – How Payers in the US & Europe are adapting to the ATMP revolution
So what are ATMPs exactly and why all the fuss about these therapies and the impact they are having within the market? Inbeeo hosted a free to attend webinar looking into this topic focusing on some specific country challenges within the US and EU, with 60+ attendees contributing to the discussion during the Q&A.

Drug R&D Public Funding – The Next Level Of Price Transparency Policies?
French lawmakers are setting the scene for a showdown with manufacturers defending their drug prices with R&D investment figures.

Tackling Rising Drug Costs in the US: Is ERP an Option?
Rising drug prices in the US are hot topic. Inbeeo takes a look at the recent drug pricing proposal by the Democrats suggesting the use of ERP.

4 Take-Away Messages From The Zolgensma® Pricing Storm
Was the reaction to the $2.15m Zolgensma list price a tropical cyclone or more of a storm in a teacup?

Decoding the data: Analytics of Drug Pricing Tweets
Inbeeo’s analysis of 2018 drug pricing tweets using NLP machine learning techniques highlight how emotive the issue of pharmaceutical pricing really is.